Human KidneyMAP® v. 1.0
The Myriad RBM KidneyMAP panels detect early signs of renal damage which is a common problem in drug development programs. Developed in conjunction with the Predictive Safety Testing Consortium, it provides a sensitive and quantitative method to detect the earliest stages of drug-induced kidney injury. This will allow researchers to efficiently prioritize drug compounds and to accelerate decisions on exploratory and clinical testing protocols.
Click or mouse over biomarkers for more information.
Analytes included in this MAP are subject to change.
Intended for Research Use Only.